Skip to main content

Table 2 Randomised participants by website group

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable

Website only

Website with support

No website

Test

N = 45

N = 45

N = 45

Age (years), mean (SD)

45.76 (9.21)

45.13 (10.13)

42.18 (11.48)

F(2,132) = 1.524, p = 0.222

Length of symptoms (years), mean (SD)

10.51 (8.19)

12.87 (9.47)

9.00 (8.14)

KW, ap = 0.129

  Median (IQR)

10.00 (12.00)

12.00 (15.00)

7.50 (8.75)

 

IBS-SSS total, mean (SD)

237.33 (85.36)

237.30 (100.78)

251.36 (75.92)

F(2,132) = 0.377, p = 0.687

IBS-QOL score, mean (SD)

67.32 (17.89)

60.00 (3.13)

64.86 (19.39)

F(2,132) = 1.65, p = 0.20

HADS score for anxiety, mean (SD)

8.73 (3.40)

9.46 (3.91)

10.00 (4.12)

F(2,132) = 1.23, p = 0.30

HADS score for depression, mean (SD)

4.20 (2.87)

5.26 (3.68)

5.32 (3.56)

KW, ap = 0.263

  Median (IQR)

4 (4)

5 (6)

5 (5)

 

Deprivation score, mean (SD)

12.27 (9.07)

8.65 (5.54)

12.81 (9.40)

KW, ap = 0.026*

  Median (IQR)

10.06 (9.79)

6.57 (7.63)

9.79 (9.21)

 

Gender n (%)

    

  Male

14 (46.7)

12 (40.0)

4 (13.3)

X2(2) = 6.844, p = 0.034*

  Female

31(29.5)

34 (32.4)

40 (38.1)

 

Type of IBS n (%)

   

X2(4) = 0.70, p = 0.953

  Constipation

5 (38.5)

5 (38.5)

3 (23.1)

 

  Diarrhoea

14 (34.1)

13 (31.7)

14 (34.1)

 

  Mixed

26 (32.1)

28 (34.6)

27 (33.3)

 

Severity IBS on IBS SSS n (%)

    

  Mild

10 (33.3)

12 (40.0)

8 (26.7)

X2(4) = 1.37, p = 0.85

  Moderate

24 (32.4)

23 (31.1)

27 (36.5)

 

  Severe

11 (35.5)

11 (35.5)

9 (29.0)

 

Education n (%)

   

X2(10) = 3.65, p = 0.97

  No formal

2 (25.0)

4 (50.0)

2 (25.0)

 

  GSCE/O

11 (31.4)

11 (31.4)

13 (37.1)

 

  A level

11 (32.4)

10 (29.4)

13 (38.2)

 

  Degree

12 (38.7)

10 (32.3)

9 (29.0)

 

  Postgraduate

5 (33.3)

7 (46.7)

3 (20.0)

 

  Other

4 (33.3)

4 (33.3)

4 (33.3)

Â